Literature DB >> 12234397

Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis.

Jack P Rock1, David Hearshen, Lisa Scarpace, David Croteau, Jorge Gutierrez, James L Fisher, Mark L Rosenblum, Tom Mikkelsen.   

Abstract

OBJECTIVE: The differentiation of tumor recurrence from radiation necrosis in patients with malignant gliomas who have been treated previously remains a challenge. Magnetic resonance imaging, single-photon emission computed tomography, and positron emission tomography cannot provide definitive histopathological insight. Multivoxel proton magnetic resonance spectroscopic imaging ((1)H MRSI) may be reliable in guiding the clinical management of untreated patients; however, its value in managing previously treated patients remains unclear.
METHODS: Twenty-seven patients who had been treated previously with surgery, radiotherapy, and chemotherapy and reoperated for clinical and/or radiographic signs that caused suspicion for recurrent disease were studied. Tissues were categorized into four groups: spectroscopically normal, pure tumor, mixed tumor and radiation necrosis, and pure radiation necrosis. Spectral data for choline (Cho), lipid-lactate (Lip-Lac), N-acetylaspartate, and creatine (Cr) were analyzed as Cho/normal Cr (nCr), Lip-Lac/Cho, Lip-Lac/nCr, N-acetylaspartate/Cho, N-acetylaspartate/nCr, and Cho/normal Cho (nCho). Stereotactic biopsies were obtained within 48 hours of (1)H MRSI and were directly correlated digitally with (1)H MRSI data. Logistic regression analysis was performed on the basis of data obtained from 99 (1)H MRSI observations to determine whether the (1)H MRSI ratios varied according to tissue category.
RESULTS: (1)H MRSI ratios were found to distinguish pure tumor from pure necrosis. The odds of a biopsy's being pure tumor and having either a Cho/nCr value greater than 1.79 or a Lip-Lac/Cho value less than 0.75 are seven times the odds of that biopsy's being pure necrosis (odds ratio, 7.00; P = 0.0136). The odds of a biopsy's being pure necrosis and having either a Cho/nCr value less than 0.89 or a Cho/nCho value less than 0.66 are six times the odds of that biopsy's being pure tumor (odds ratio, 5.71; P = 0.0329). The odds of a biopsy's being pure necrosis and having either a Lip-Lac/Cho value greater than 1.36 or a Lip-Lac/nCr value greater than 2.84 are more than five times the odds of the biopsy's being pure tumor (odds ratio, 5.25; P = 0.0322). In addition, although only marginally significant, Lip-Lac/Cho and Lip-Lac/nCr ratios distinguish pure tumor from pure necrosis. No values suggested that mixed specimens could be distinguished in a statistically significant way from either pure tumor or pure necrosis.
CONCLUSION: The data that we gathered suggest that metabolite ratios derived on the basis of (1)H MRSI spectral patterns do allow reliable differential diagnostic statements to be made when the tissues are composed of either pure tumor or pure necrosis, but the spectral patterns are less definitive when tissues composed of varying degrees of mixed tumor and necrosis are examined.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234397     DOI: 10.1097/00006123-200210000-00010

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  61 in total

1.  The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas.

Authors:  Jun Guo; Chengjun Yao; Hong Chen; Dongxiao Zhuang; Weijun Tang; Guang Ren; Yin Wang; Jinsong Wu; Fengping Huang; Liangfu Zhou
Journal:  Acta Neurochir (Wien)       Date:  2012-06-23       Impact factor: 2.216

Review 2.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

Review 3.  Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology.

Authors:  Alba A Brandes; Alicia Tosoni; Federica Spagnolli; Giampiero Frezza; Marco Leonardi; Fabio Calbucci; Enrico Franceschi
Journal:  Neuro Oncol       Date:  2008-04-09       Impact factor: 12.300

4.  Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Ramon F Barajas; Jamie S Chang; Mark R Segal; Andrew T Parsa; Michael W McDermott; Mitchel S Berger; Soonmee Cha
Journal:  Radiology       Date:  2009-09-29       Impact factor: 11.105

5.  Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies.

Authors:  J M Hoxworth; J M Eschbacher; A C Gonzales; K W Singleton; G D Leon; K A Smith; A M Stokes; Y Zhou; G L Mazza; A B Porter; M M Mrugala; R S Zimmerman; B R Bendok; D P Patra; C Krishna; J L Boxerman; L C Baxter; K R Swanson; C C Quarles; K M Schmainda; L S Hu
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

6.  Recurrent glioblastoma multiforme versus radiation injury: a multiparametric 3-T MR approach.

Authors:  Alfonso Di Costanzo; Tommaso Scarabino; Francesca Trojsi; Teresa Popolizio; Simona Bonavita; Mario de Cristofaro; Renata Conforti; Adriana Cristofano; Claudio Colonnese; Ugo Salvolini; Gioacchino Tedeschi
Journal:  Radiol Med       Date:  2014-01-10       Impact factor: 3.469

7.  Chordoid glioma of the third ventricle: report of a rapidly progressive case.

Authors:  Amalie A Erwood; Jose E Velazquez-Vega; Stewart Neill; David A Solomon; Nicholas Butowski; Adam Nowlan; Erin Dunbar; Daniel J Brat
Journal:  J Neurooncol       Date:  2017-03-18       Impact factor: 4.130

8.  Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.

Authors:  Morad Nasseri; Seymur Gahramanov; Joao Prola Netto; Rongwei Fu; Leslie L Muldoon; Csanad Varallyay; Bronwyn E Hamilton; Edward A Neuwelt
Journal:  Neuro Oncol       Date:  2014-02-11       Impact factor: 12.300

9.  Brain irradiation: effects on normal brain parenchyma and radiation injury.

Authors:  Pia C Sundgren; Yue Cao
Journal:  Neuroimaging Clin N Am       Date:  2009-11       Impact factor: 2.264

10.  Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.

Authors:  Eiji Matsusue; James R Fink; Jason K Rockhill; Toshihide Ogawa; Kenneth R Maravilla
Journal:  Neuroradiology       Date:  2009-10-16       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.